ANDA 210575, held by Zydus Pharms. Atazanavir Sulfate.
As of Nov 15, 2026, ANDA 210575 (Atazanavir Sulfate), held by Zydus Pharms, was first approved by FDA on Jun 4, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 4, 2020 | Original application | Approved | None posted |
| Atazanavir SulfateEQ 150MG BASE · capsule;oral | Atazanavir Sulfate | Discontinued |
| Atazanavir SulfateEQ 200MG BASE · capsule;oral | Atazanavir Sulfate | Discontinued |
| Atazanavir SulfateEQ 300MG BASE · capsule;oral | Atazanavir Sulfate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
